Literature DB >> 24880950

Combinatorial approach to treatment of melanoma.

Michelle T Ashworth1, Adil I Daud2.   

Abstract

There are multiple effective and well-tolerated systemic therapy treatments for the treatment of advanced melanoma, as well as new immunotherapy and targeted therapy agents in clinical trials. Traditional cytotoxic chemotherapy and targeted BRAF inhibitors can increase antigen presentation and can rebalance the intratumoral immune milieu. The combination of pulsed cytotoxic therapy and immunotherapy is a logical next step in designing treatment regimens. Combination radiotherapy and immunotherapy also has experimental and clinical support. The standard of care for patients with advanced melanoma remains participation in clinical trials in order to enhance understanding of the effectiveness and toxicities of combination regimens.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRAF; Combination therapy; Immunotherapy; Melanoma; Mitogen-activated extracellular kinase; Targeted therapy

Mesh:

Year:  2014        PMID: 24880950     DOI: 10.1016/j.hoc.2014.03.002

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  1 in total

1.  Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells.

Authors:  Mary Jc Hendrix; Irawati Kandela; Andrew P Mazar; Elisabeth A Seftor; Richard Eb Seftor; Naira V Margaryan; Luigi Strizzi; George F Murphy; Georgina V Long; Richard A Scolyer
Journal:  Lab Invest       Date:  2016-10-24       Impact factor: 5.662

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.